Jafarzadeh Leila, Masoumi Elham, Fallah-Mehrjardi Keyvan, Mirzaei Hamid Reza, Hadjati Jamshid
Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Department of Medical Immunology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Front Immunol. 2020 Apr 22;11:702. doi: 10.3389/fimmu.2020.00702. eCollection 2020.
CAR T cell qualities, such as persistence and functionality play important roles in determining the outcome of cancer immunotherapy. In spite of full functionality, it has been shown that poor persistence of CAR T cells can limit an effective antitumor immune response. Here, we outline specific strategies that can be employed to overcome intrinsic and extrinsic barriers to CAR T cell persistence. We also offer our viewpoint on how growing use of CAR T cells in various cancers may require modifications in the intrinsic and extrinsic survival signals of CAR T cells. We anticipate these amendments will additionally provide the rationales for generation of more persistent, and thereby, more effective CAR T cell treatments. CAR T cell qualities, such as persistence and functionality play important roles in determining the outcome of cancer immunotherapy. In spite of full functionality, it has been shown that poor persistence of CAR T cells can limit an effective antitumor immune response. Here, we outline specific strategies that can be employed to overcome intrinsic and extrinsic barriers to CAR T cell persistence. We also offer our viewpoint on how growing use of CAR T cells in various cancers may require modifications in the intrinsic and extrinsic survival signals of CAR T cells. We anticipate these amendments will additionally provide the rationales for generation of more persistent, and thereby, more effective CAR T cell treatments.
Cancer Cell. 2020-10-12
Mamm Genome. 2018-7-9
Annu Rev Med. 2016-11-17
Hepatobiliary Pancreat Dis Int. 2018-5-24
J Hematol Oncol. 2020-5-18
Mol Ther Nucleic Acids. 2025-8-11
Pharmaceuticals (Basel). 2025-8-4
Int J Hematol Oncol Stem Cell Res. 2025-4-1
Curr Issues Mol Biol. 2025-4-10
Mol Ther. 2025-6-4
Immunotherapy. 2024
J Immunother Cancer. 2024-8-7
Vaccines (Basel). 2024-6-12
Mol Ther Oncolytics. 2019-8-28
Oncoimmunology. 2018-3-15
Mol Ther Methods Clin Dev. 2017-11-7